Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
暂无分享，去创建一个
B. Pégourié | O. Decaux | C. Sebban | P. Moreau | H. Avet-Loiseau | G. Marit | C. Mathiot | T. Facon | J. Harousseau | C. Doyen | M. Attal | C. Berthou | L. Garderet | A. Stoppa | C. Chaleteix | M. Tiab | C. Araujo | P. Lenain | M. Wetterwald | C. Hulin | D. Caillot | L. Benboubker | B. Lioure | G. Lepeu | Edouard Randriamalala | M. Escoffre | M. Dib | C. Traullé | J. Fontan | J. Fuzibet | B. Kolb